|
1
|
Global Burden of Disease Cancer
Collaboration, . Fitzmaurice C, Abate D, Abbasi N, Abbastabar H,
Abd-Allah F, Abdel-Rahman O, Abdelalim A, Abdoli A, Abdollahpour I,
et al: Global, regional, and national cancer incidence, mortality,
years of life lost, years lived with disability, and
disability-adjusted life-years for 29 cancer groups, 1990 to 2017:
A systematic analysis for the global burden of disease study. JAMA
Oncol. 5:1749–1768. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chandra R, Balachandar N, Wang S, Reznik
S, Zeh H and Porembka M: The changing face of gastric cancer:
Epidemiologic trends and advances in novel therapies. Cancer Gene
Ther. 28:390–399. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yin S, Wang P, Xu X, Tan Y, Huang JY and
Xu HM: The optimal strategy of multimodality therapies for
resectable gastric cancer: Evidence from a network meta-analysis. J
Cancer. 10:3094–3101. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hu Y, Hu D, Li W and Yu XJ: Neoadjuvant
chemotherapy brings more survival benefits than postoperative
chemotherapy for resectable gastric cancer: A meta-analysis of
randomized controlled trials. J BUON. 24:201–214. 2019.PubMed/NCBI
|
|
5
|
Newton AD, Datta J, Loaiza-Bonilla A,
Karakousis GC and Roses RE: Neoadjuvant therapy for gastric cancer:
Current evidence and future directions. J Gastrointest Oncol.
6:534–543. 2015.PubMed/NCBI
|
|
6
|
Songun I, Keizer HJ, Hermans J,
Klementschitsch P, de Vries JE, Wils JA, van der Bijl J, van
Krieken JH and van de Velde C: Chemotherapy for operable gastric
cancer: Results of the Dutch randomised FAMTX trial. The Dutch
Gastric Cancer Group (DGCG). Eur J Cancer. 35:558–562. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hartgrink HH, Velde CJ, Putter H, Songun
I, Tesselaar ME, Kranenbarg EK, de Vries JE, Wils JA, van der Bijl
J and van Krieken JH; Cooperating Investigators of The Dutch
Gastric Cancer Group, : Neo-adjuvant chemotherapy for operable
gastric cancer: Long term results of the Dutch randomised FAMTX
trial. Eur J Surg Oncol. 30:643–649. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cunningham D, Allum WH, Stenning SP,
Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ,
Falk SJ, Iveson TJ, et al: Perioperative chemotherapy versus
surgery alone for resectable gastroesophageal cancer. N Engl J Med.
355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schuhmacher C, Gretschel S, Lordick F,
Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan
B, Welch J, et al: Neoadjuvant chemotherapy compared with surgery
alone for locally advanced cancer of the stomach and cardia:
European Organisation for Research and Treatment of Cancer
randomized trial 40954. J Clin Oncol. 28:5210–5218. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Alderson D, Cunningham D, Nankivell M,
Blazeby JM, Griffin SM, Crellin A, Grabsch HI, Langer R, Pritchard
S, Okines A, et al: Neoadjuvant cisplatin and fluorouracil versus
epirubicin, cisplatin, and capecitabine followed by resection in
patients with oesophageal adenocarcinoma (UK MRC OE05): An
open-label, randomised phase 3 trial. Lancet Oncol. 18:1249–1260.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ychou M, Boige V, Pignon JP, Conroy T,
Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM,
Saint-Aubert B, et al: Perioperative chemotherapy compared with
surgery alone for resectable gastroesophageal adenocarcinoma: An
FNCLCC and FFCD multicenter phase III trial. J Clin Oncol.
29:1715–1721. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Al-Batran S, Hofheinz RD, Pauligk C, Kopp
HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg
H, et al: Histopathological regression after neoadjuvant docetaxel,
oxaliplatin, fluorouracil, and leucovorin versus epirubicin,
cisplatin, and fluorouracil or capecitabine in patients with
resectable gastric or gastro-oesophageal junction adenocarcinoma
(FLOT4-AIO): Results from the phase 2 part of a multicentre,
open-label, randomised phase 2/3 trial. Lancet Oncol. 17:1697–1708.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Al-Batran S, Homann N, Pauligk C, Goetze
TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, et al:
Perioperative chemotherapy with fluorouracil plus leucovorin,
oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus
cisplatin and epirubicin for locally advanced, resectable gastric
or gastro-oesophageal junction adenocarcinoma (FLOT4): A
randomised, phase 2/3 trial. Lancet. 393:1948–1957. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
National Comprehensive Cancer Network
(NCCN), . NCCN Clinical Practice Guidelines in Oncology (NCCN
Guidelines®): Gastric cancer (version 2). NCCN; Plymouth
Meeting, PA: 2018, www.nccn.orgMay 22–2018
|
|
15
|
Li ZY, Koh CE, Bu ZD, Wu AW, Zhang LH, Wu
XJ, Wu Q, Zong XL, Ren H, Tang L, et al: Neoadjuvant chemotherapy
with FOLFOX: Improved outcomes in Chinese patients with locally
advanced gastric cancer. J Surg Oncol. 105:793–799. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kochi M, Fujii M, Kanamori N, Mihara Y,
Funada T, Tamegai H, Watanabe M, Takayama Y, Suda H and Takayama T:
Phase II study of neoadjuvant chemotherapy with S-1 and CDDP in
patients with lymph Node metastatic stage II or III gastric cancer.
Am J Clin Oncol. 40:17–21. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Terashima M, Iwasaki Y, Mizusawa J,
Katayama H, Nakamura K, Katai H, Yoshikawa T, Ito Y, Kaji M, Kimura
Y, et al: Randomized phase III trial of gastrectomy with or without
neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric
cancer, the short-term safety and surgical results: Japan Clinical
Oncology Group Study (JCOG0501). Gastric Cancer. 22:1044–1052.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang X, Liang H, Li Z, Xue Y, Wang Y,
Zhou Z, Yu J, Bu Z, Chen L, Du Y, et al: Perioperative or
postoperative adjuvant oxaliplatin with S-1 versus adjuvant
oxaliplatin with capecitabine in patients with locally advanced
gastric or gastro-oesophageal junction adenocarcinoma undergoing D2
gastrectomy (RESOLVE): An open-label, superiority and
non-inferiority, phase 3 randomised controlled trial. Lancet Oncol.
22:1081–1092. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Smyth EC, Verheij M, Allum W, Cunningham
D, Cervantes A and Arnold D; ESMO Guidelines Committee, : Gastric
cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment
and follow-up. Ann Oncol. 27 (Suppl 5):v38–v49. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang FH, Zhang XT, Li F, Tang L, Qu XJ,
Ying JE, Zhang J, Sun LY, Lin RB, Qiu H, et al: The Chinese Society
of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis
and treatment of gastric cancer, 2021. Cancer Commun (Lond).
41:747–795. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tokunaga M, Sato Y, Nakagawa M, Aburatani
T, Matsuyama T, Nakajima Y and Kinugasa Y: Perioperative
chemotherapy for locally advanced gastric cancer in Japan: Current
and future perspectives. Surg Today. 50:30–37. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yoshikawa T, Morita S, Tanabe K, Nishikawa
K, Ito Y, Matsui T, Fujitani K, Kimura Y, Fujita J, Aoyama T, et
al: Survival results of a randomised two-by-two factorial phase II
trial comparing neoadjuvant chemotherapy with two and four courses
of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC)
followed by D2 gastrectomy for resectable advanced gastric cancer.
Eur J Cancer. 62:103–111. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Macdonald JS, Smalley SR, Benedetti J,
Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA,
Gunderson LL, Jessup JM and Martenson JA: Chemoradiotherapy after
surgery compared with surgery alone for adenocarcinoma of the
stomach or gastroesophageal junction. N Engl J Med. 345:725–730.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee J, Lim DH, Kim S, Park SH, Park JO,
Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, et al: Phase III trial
comparing capecitabine plus cisplatin versus capecitabine plus
cisplatin with concurrent capecitabine radiotherapy in completely
resected gastric cancer with D2 lymph node dissection: The ARTIST
trial. J Clin Oncol. 30:268–273. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stahl M, Walz MK, Riera-Knorrenschild J,
Stuschke M, Sandermann A, Bitzer M, Wilke H and Budach W:
Preoperative chemotherapy versus chemoradiotherapy in locally
advanced adenocarcinomas of the oesophagogastric junction (POET):
Long-term results of a controlled randomised trial. Eur J Cancer.
81:183–190. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Stahl M, Walz MK, Stuschke M, Lehmann N,
Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R,
Bitzer M, Königsrainer A, et al: Phase III comparison of
preoperative chemotherapy compared with chemoradiotherapy in
patients with locally advanced adenocarcinoma of the
esophagogastric junction. J Clin Oncol. 27:851–856. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Klevebro F, Alexandersson von Döbeln G,
Wang N, Johnsen G, Jacobsen AB, Friesland S, Hatlevoll I, Glenjen
NI, Lind P, Tsai JA, et al: A randomized clinical trial of
neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for
cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol.
27:660–667. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
van Hagen P, Hulshof MC, van Lanschot JJ,
Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ,
Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al: Preoperative
chemoradiotherapy for esophageal or junctional cancer. N Engl J
Med. 366:2074–2084. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shapiro J, van Lanschot JJB, Hulshof MCCM,
van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven
HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, et al:
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for
oesophageal or junctional cancer (CROSS): Long-term results of a
randomised controlled trial. Lancet Oncol. 16:1090–1098. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Leong T, Smithers BM, Haustermans K,
Michael M, Gebski V, Miller D, Zalcberg J, Boussioutas A, Findlay
M, O'Connell RL, et al: TOPGEAR: A randomized, phase III trial of
perioperative ECF chemotherapy with or without preoperative
chemoradiation for resectable gastric cancer: Interim results from
an international, intergroup trial of the AGITG, TROG, EORTC and
CCTG. Ann Surg Oncol. 24:2252–2258. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nagaraja AK, Kikuchi O and Bass AJ:
Genomics and targeted therapies in gastroesophageal adenocarcinoma.
Cancer Discov. 9:1656–1672. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Patel TH and Cecchini M: Targeted
therapies in advanced gastric cancer. Curr Treat Options Oncol.
21:702020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gong J, Liu T, Fan Q, Bai L, Bi F, Qin S,
Wang J, Xu N, Cheng Y, Bai Y, et al: Optimal regimen of trastuzumab
in combination with oxaliplatin/capecitabine in first-line
treatment of HER2-positive advanced gastric cancer (CGOG1001): A
multicenter, phase II trial. BMC Cancer. 16:682016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ohtsu A, Shah MA, Van Cutsem E, Rha SY,
Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, et al:
Bevacizumab in combination with chemotherapy as first-line therapy
in advanced gastric cancer: A randomized, double-blind,
placebo-controlled phase III study. J Clin Oncol. 29:3968–3976.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shen L, Li J, Xu J, Pan H, Dai G, Qin S,
Wang L, Wang J, Yang Z, Shu Y, et al: Bevacizumab plus capecitabine
and cisplatin in Chinese patients with inoperable locally advanced
or metastatic gastric or gastroesophageal junction cancer:
Randomized, double-blind, phase III study (AVATAR study). Gastric
Cancer. 18:168–176. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Keam SJ: Trastuzumab deruxtecan: First
approval. Drugs. 80:501–508. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cunningham D, Stenning SP, Smyth EC,
Okines AF, Allum WH, Rowley S, Stevenson L, Grabsch HI, Alderson D,
Crosby T, et al: Peri-operative chemotherapy with or without
bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical
Research Council ST03): Primary analysis results of a multicentre,
open-label, randomised phase 2–3 trial. Lancet Oncol. 18:357–370.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zheng Y, Yang X, Yan C, Feng R, Sah BK,
Yang Z, Zhu Z, Liu W, Xu W, Ni Z, et al: Effect of apatinib plus
neoadjuvant chemotherapy followed by resection on pathologic
response in patients with locally advanced gastric adenocarcinoma:
A single-arm, open-label, phase II trial. Eur J Cancer. 130:12–19.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hofheinz RD, Hegewisch-Becker S, Kunzmann
V, Thuss-Patience P, Fuchs M, Homann N, Graeven U, Schulte N, Merx
K, Pohl M, et al: Trastuzumab in combination with 5-fluorouracil,
leucovorin, oxaliplatin and docetaxel as perioperative treatment
for patients with human epidermal growth factor receptor 2-positive
locally advanced esophagogastric adenocarcinoma: A phaseII trial of
the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer
Study Group. Int J Cancer. 149:1322–1331. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wagner AD, Grabsch HI, Mauer M, Marreaud
S, Caballero C, Thuss-Patience P, Mueller L, Elme A, Moehler MH,
Martens U, et al: EORTC-1203-GITCG-the ‘INNOVATION’-trial: Effect
of chemotherapy alone versus chemotherapy plus trastuzumab, versus
chemotherapy plus trastuzumab plus pertuzumab, in the perioperative
treatment of HER2 positive, gastric and gastroesophageal junction
adenocarcinoma on pathologic response rate: A randomized phase
II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer
Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
BMC Cancer. 19:4942019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chiari D, Orsenigo E, Guarneri G, Baiocchi
GL, Mazza E, Albarello L, Bissolati M, Molfino S and Staudacher C;
Gruppo Italiano Ricerca Cancro Gastrico (GIRCG), : Effect of
neoadjuvant chemotherapy on HER-2 expression in surgically treated
gastric and oesophagogastric junction carcinoma: A multicentre
Italian study. Updates Surg. 69:35–43. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bozkaya Y, Özdemir NY, Sezer S, Köstek O,
Demirci NS, Yazıcı O, Erdem GU, Eren T and Zengin N: Is serum
survivin expression a predictive biomarker in locally advanced
gastric cancer patients treated with neoadjuvant chemotherapy?
Cancer Biomark. 22:143–149. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ren S, Zhang Z, Xu C, Guo L, Lu R, Sun Y,
Guo J, Qin R, Qin W and Gu J: Distribution of IgG galactosylation
as a promising biomarker for cancer screening in multiple cancer
types. Cell Res. 26:963–966. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Qin R, Yang Y, Qin W, Han J, Chen H, Zhao
J, Zhao R, Li C, Gu Y, Pan Y, et al: The value of serum
immunoglobulin G glycome in the preoperative discrimination of
peritoneal metastasis from advanced gastric cancer. J Cancer.
10:2811–2821. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Qin R, Yang Y, Chen H, Qin W, Han J, Gu Y,
Pan Y, Cheng X, Zhao J, Wang X, et al: Prediction of neoadjuvant
chemotherapeutic efficacy in patients with locally advanced gastric
cancer by serum IgG glycomics profiling. Clin Proteomics. 17:42020.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tan B, Li Y, Di Y, Fan L, Zhao Q, Liu Q,
Wang D and Jia N: Clinical value of peripheral blood microRNA
detection in evaluation of SOX regimen as neoadjuvant chemotherapy
for gastric cancer. J Clin Lab Anal. 32:e223632018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Xu C, Cheng H, Li N, Zhou N and Tang X:
Relationship between microRNA-27a and efficacy of neoadjuvant
chemotherapy in gastric cancer and its mechanism in gastric cancer
cell growth and metastasis. Biosci Rep. 39:BSR201811752019.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sánchez-Izquierdo N, Perlaza P, Pagès M,
Buxó E, Rios J, Rubello D, Colletti PM, Mayoral M, Casanueva S,
Fernández-Esparrach G, et al: Assessment of response to neoadjuvant
chemoradiotherapy by 18F-FDG PET/CT in patients with locally
advanced esophagogastric junction adenocarcinoma. Clin Nucl Med.
45:38–43. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lee JW, Jo K, Cho A, Noh SH, Lee JD and
Yun M: Relationship between 18F-FDG uptake on PET and recurrence
patterns after curative surgical resection in patients with
advanced gastric cancer. J Nucl Med. 56:1494–1500. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chen R, Zhou X, Liu JJ and Huang G:
Relationship between18F-FDG PET/CT findings and HER2 expression in
gastric cancer. J Nucl Med. 57:1040–1044. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
Organization for Research and Treatment of Cancer, National Cancer
Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Becker K, Mueller JD, Schulmacher C, Ott
K, Fink U, Busch R, Böttcher K, Siewert JR and Höfler H:
Histomorphology and grading of regression in gastric carcinoma
treated with neoadjuvant chemotherapy. Cancer. 98:1521–1530. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Liang JX, Bi XJ, Li XM, Gao ZL, Suo F, Cui
EG, Li HF and Lv HL: Evaluation of multislice spiral computed
tomography perfusion imaging for the efficacy of preoperative
concurrent chemoradiotherapy in middle-aged and elderly patients
with locally advanced gastric cancer. Med Sci Moni. 24:235–245.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Huang P, Li S, Aronow WS, Wang Z, Nair CK,
Xue N, Shen X, Chen C and Cosgrove D: Double contrast-enhanced
ultrasonography evaluation of preoperative Lauren classification of
advanced gastric carcinoma. Arch Med Sci. 7:287–293. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Becker K, Langer R, Reim D, Novotny A,
Meyer zum Buschenfelde C, Engel J, Friess H and Hofler H:
Significance of histopathological tumor regression after
neoadjuvant chemotherapy in gastric adenocarcinomas. Ann Surg.
253:934–939. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Japanese Gastric Cancer Association.
Japanese classification of gastric carcinoma, . (3rd English
edition). Gastric Cancer. 14:101–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Smyth EC, Fassan M, Cunningham D, Allum
WH, Okines AF, Lampis A, Hahne JC, Rugge M, Peckitt C, Nankivell M,
et al: Effect of pathologic tumor response and nodal status on
survival in the medical research council adjuvant gastric
infusional chemotherapy trial. J Clin Oncol. 34:2721–2727. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Tomasello G, Petrelli F, Ghidini M,
Pezzica E, Passalacqua R, Steccanella F, Turati L, Sgroi G and
Barni S: Tumor regression grade and survival after neoadjuvant
treatment in gastro-esophageal cancer: A meta-analysis of 17
published studies. Eur J Surg Oncol. 43:1607–1616. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kim MS, Lim JS, Hyung WJ, Lee YC, Rha SY,
Keum KC and Koom WS: Neoadjuvant chemoradiotherapy followed by D2
gastrectomy in locally advanced gastric cancer. World J
Gastroenterol. 21:2711–2718. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Leong T: A CRITICal period for
chemoradiotherapy in gastric cancer. Lancet Oncol. 19:581–583.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Fornaro L, Vasile E, Aprile G, Goetze TO,
Vivaldi C, Falcone A and Al-Batran SE: Locally advanced
gastro-oesophageal cancer: Recent therapeutic advances and research
directions. Cancer Treat Rev. 69:90–100. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Cats A, Jansen EPM, van Grieken NCT,
Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot
H, Trip AK, Swellengrebel HAM, et al: Chemotherapy versus
chemoradiotherapy after surgery and preoperative chemotherapy for
resectable gastric cancer (CRITICS): An international, open-label,
randomised phase 3 trial. Lancet Oncol. 19:616–628. 2018.
View Article : Google Scholar : PubMed/NCBI
|
